FDAers Sink Mevacor OTC At Panel Meeting With Unflinching Critique
Two key presentations by FDA reviewers of Mevacor OTC study data may have undermined any chances of J&J/Merck's salvaging a favorable recommendation to switch the drug
Two key presentations by FDA reviewers of Mevacor OTC study data may have undermined any chances of J&J/Merck's salvaging a favorable recommendation to switch the drug